


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



C<sub>3-7</sub>cycloalkyl or phenyl;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is halogen, trifluoromethyl or nitrile;

R<sub>6</sub> is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub> alkyl, amino or hydroxy;

R<sub>7</sub> is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub>alkyl, ~~optionally substituted-amino~~  
optionally substituted with one or more of the same or

different kinds of straight-chained or branched C<sub>1-3</sub> alkyl, or  
hydroxy;

R<sub>8</sub> is hydrogen, methyl or ethyl;

R<sub>9</sub> is optionally substituted straight-chained or  
branched C<sub>1-6</sub> alkyl, optionally substituted straight-chained or  
branched C<sub>2-6</sub>alkenyl, optionally substituted straight-chained  
or branched C<sub>2-6</sub>alkynyl, C<sub>3-7</sub>cycloalkyl or optionally  
substituted phenyl;


R<sub>20</sub> is hydrogen or straight-chained or branched  
C<sub>1-3</sub>alkyl or R<sub>9</sub> and R<sub>20</sub> may together form C<sub>3-7</sub>cycloalkyl;

R<sub>10</sub> is hydrogen or straight-chained or branched  
C<sub>1-3</sub>alkyl;

R<sub>11</sub> is hydrogen, straight-chained or branched C<sub>1-3</sub>  
alkyl optionally substituted with one or more groups which may  
be the same or different and are selected from the group  
consisting of amino optionally substituted with one or more of  
the same or different straight-chained or branched C<sub>1-3</sub> alkyl;  
3- to 7-membered cyclic amino optionally substituted with  
hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl,  
methoxy, halogen, carbamoyl, methanesulfonyl, ureide,  
guanidyl, N'-cyano-N''-methylguanidyl, sulfamoylamino,  
carbamoylmethylamino and methanesulfonylamino, -CO-N(R<sub>14</sub>)R<sub>15</sub>,  
carboxyl;

R<sub>12</sub> is hydroxy or -OR<sub>16</sub>;

R<sub>13</sub> is hydrogen, straight-chained or branched C<sub>1-6</sub> alkyl, straight-chained or branched C<sub>2-6</sub>alkenyl, straight-chained or branched C<sub>2-6</sub>alkynyl or a group of Formula (3):



R<sub>14</sub> and R<sub>15</sub>, which may be the same or different, are each hydrogen, straight-chained or branched C<sub>1-3</sub> alkyl optionally substituted with straight-chained or branched C<sub>1-3</sub> alkoxy optionally substituted with hydroxyl, amino, carboxyl or carbamoyl; hydroxyl; amino; methylamino; dimethylamino; carbamoyl or methanesulfonyl; optionally substituted straight-chained or branched C<sub>1-4</sub> alkyl, C<sub>3-7</sub>cycloalkyl, straight-chained or branched C<sub>1-4</sub> alkoxy, straight-chained or branched C<sub>1-4</sub> alkylsulfonyl or a heterocyclic ring;

R<sub>16</sub> is straight-chained C<sub>1-4</sub> alkyl;

R<sub>17</sub> is hydrogen or methyl;

R<sub>18</sub> and R<sub>19</sub> together form cycloalkyl or C<sub>3-7</sub> cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2);  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

3. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which  
at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is halogen and the others  
are hydrogen or hydroxy;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

4. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which  
R<sub>3</sub> is halogen or R<sub>2</sub> and R<sub>3</sub> are the same kind of halogen;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

5. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which  
R<sub>3</sub> is halogen and R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen, or R<sub>2</sub> and R<sub>3</sub>  
are the same kind of halogen and R<sub>1</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

6. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is trifluoromethyl and the others are hydrogen, halogen or hydroxy;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

7. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is nitrile and the others are hydrogen, halogen or hydroxy;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

8. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is trifluoromethyl;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

9. (Currently Amended) The compound according to claim 1,  
wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is nitrile;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

Claims 10-12. (Canceled)

13. (Currently Amended) The compound according to claim 1, wherein  $R_6$  in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

14. (Currently Amended) The compound according to claim 1, wherein  $R_7$  in Formula (1) is hydrogen or ~~optionally substituted amino~~ optionally substituted with one or more of the same of different kinds of straight-chained or branched  $C_{1-3}$  alkyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

15. (Currently Amended) The compound according to claim 1, wherein  $R_8$  in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

16. (Currently Amended) The compound according to claim 1, wherein  $R_9$  in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

17. (Currently Amended) The compound according to claim 1, wherein  $R_{20}$  in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

18. (Currently Amended) The compound according to claim 1, wherein  $R_{10}$  in Formula (1) is hydrogen or methyl; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

19. (Currently Amended) The compound according to claim 1, wherein  $R_{11}$  in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

20. (Currently Amended) The compound according to claim 1, wherein  $R_{12}$  in Formula (1) is hydroxy; or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

21. (Currently Amended) The compound according to claim 1, wherein  $R_{13}$  in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

22. (Currently Amended) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2)

in which at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  is halogen and the others are hydrogen or hydroxy;

$R_6$  is hydrogen or methyl;

$R_7$  is hydrogen or ~~optionally substituted amino~~ optionally substituted with one or more of the same or different straight-chained or branched  $C_{1-3}$  alkyl;

$R_8$  is hydrogen or methyl;

$R_9$  is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;

$R_{20}$  is hydrogen;

$R_{10}$  is hydrogen or methyl;

$R_{11}$  is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tert-butylcarbamoyl, , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl,;

$R_{12}$  is hydroxy;

$R_{13}$  is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.



23. (Currently Amended) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(3,4-F<sub>2</sub>)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-

methyl-butrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Et-

Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHMe, Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHtBu, Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHCH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>, Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHET, N-Me-Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHET, N-Et-Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHET, Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Me-Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Et-Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHCH<sub>2</sub>OH, Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHET, N-Me-Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHET, N-Et-Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHET, Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Me-Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Et-Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHCH<sub>2</sub>OH, Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHET, N-Me-Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHET, N-Et-Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHET, Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Me-Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHCH<sub>2</sub>OH, N-Et-Phe (4-F) -N-Me-Val-N-Et-Tyr (3-tBu) -NHCH<sub>2</sub>OH, Phe (4-F) -N-Me-Val-N-Me-Tyr (3-tBu) -NHcPr, and Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHnPr Phe (4-F) -N-Me-Val-Tyr (3-tBu) -NHlPr;


or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Currently Amended) A compound of Formula (4):



wherein


Cy, R<sub>6</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>20</sub>, R<sub>10</sub>, R<sub>12</sub>, R<sub>13</sub>, X and Y are as defined in claim 1;

R<sub>7</sub>' is hydrogen, straight-chained or branched C<sub>1-3</sub> alkyl optionally having at least one protected substituent, amino optionally having at least one ~~protected~~ substituent of the same or different straight-chained or branched C<sub>1-3</sub> alkyl or protected hydroxyl;

R<sub>11</sub>" is hydrogen, ~~optionally substituted~~ straight-chained or branched C<sub>1-3</sub> alkyl optionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino optionally substituted with one or more of the same or different straight-chained or branched C<sub>1-3</sub> alkyl; 3- to 7-membered

cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl; methoxy; halogen; carbamoyl; methanesulfonyl; ureide; guanidyl; N'-cyano-N"-methylguanidyl; sulfamoylamino; carbamoylmethylamino; and methanesulfonylamino, -CO-N(R<sub>14</sub>)R<sub>15</sub>, wherein R<sub>14</sub> and R<sub>15</sub> are as defined in claim 1, carboxyl, straight-chained or branched C<sub>1-3</sub>alkyl having a protected amino;  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

29. (Currently Amended) A compound of Formula (5):



wherein:


Cy, R<sub>6</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>20</sub>, R<sub>10</sub>, R<sub>12</sub>, R<sub>13</sub>, X and Y are as defined in claim 1;

R<sub>7</sub>'' is hydrogen, straight-chained or branched C<sub>1-3</sub>alkyl optionally having at least optionally protected substituent, amino optionally having at least one ~~optionally protected~~ substituents which are the same or different straight-chained or branched C<sub>1-3</sub> alkyl, or optionally protected hydroxy; and

R<sub>11</sub>' is hydrogen, straight-chained or branched C<sub>1-3</sub>alkyl optionally having at least one protected substituent s which may be the same or different and are selected from the

group consisting of protected amino optionally substituted  
with one or more straight--chained or branched C<sub>1-3</sub> alkyl;  
protected 3- to 7-membered cyclic amino optionally substituted  
with protected hydroxyl, protected amino, protected carboxyl  
or protected carbamoyl; protected hydroxyl; protected  
carbamoyl; protected ureide; protected guanidyl; protected N'-  
cyano-N''-methylguanidyl; protected sulfamoylamino; protected  
carbamoylmethylamino and protected methanesulfonylamino;  $\tau$  -CO-  
N(R<sub>14</sub>)R<sub>15</sub> wherein R<sub>14</sub> and R<sub>15</sub> are as defined in claim 1, carboxyl  
or a hydrate or pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



wherein:

R<sub>8</sub> is hydrogen, optionally-substituted straight-  
chained or branched C<sub>1-3</sub> alkyl, optionally substituted amino,  
or hydroxy;


R<sub>9</sub>, is optionally-substituted straight-chained or  
branched C<sub>1-6</sub> alkyl, optionally substituted straight-chained or  
branched C<sub>2-6</sub> alkenyl, optionally substituted straight-chained  
or branched C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl or optionally  
substituted phenyl;

R<sub>20</sub> is hydrogen or straight-chained or branched C<sub>1-3</sub> alkyl; or R<sub>9</sub> and R<sub>20</sub> may together form C<sub>3-7</sub> cycloalkyl;

R<sub>10</sub> is hydrogen or straight-chain or branched C<sub>1-3</sub> alkyl;

R<sub>12</sub> is hydroxy or OR<sub>16</sub>;

R<sub>13</sub> is hydrogen, straight-chained or branched C<sub>1-6</sub> alkyl, straight-chained or branched C<sub>2-6</sub> alkenyl, straight-chained or branched C<sub>2-6</sub> alkynyl or a group of Formula (3)



Wherein R<sub>17</sub> is hydrogen or methyl;

R<sub>18</sub> and R<sub>19</sub> together form cycloalkenyl or C<sub>3-7</sub> cycloalkenyl; and

Y is carbonyl or methylene;

P<sub>1</sub> is hydrogen or a protecting group of amine; and

R<sub>11</sub>''' is hydrogen, ~~optionally substituted~~ straight-chained or branched C<sub>1-3</sub>alkyl, carboxyl, straight-chained or branched C<sub>1-3</sub>alkyloptionally substituted with one or more groups which may be the same or different and are selected from the group consisting of amino optionally substituted with one or more of the same or different straight-chained or branched C<sub>1-3</sub> alkyl; 3- to 7-membered cyclic amino optionally substituted with hydroxyl, amino, carboxyl, carbamoyl or methyl; hydroxyl; methoxy; halogen; carbamoyl; methanesulfonyl; ureide;

guanidyl; N'-cyano-N''-methylguanidyl; sulfamoylamino;  
carbamoylmethylamino and methanesulfonylamino; carboxyl,  
straight-chained or branched C<sub>1-3</sub> alkyl having protected amino  
or an optionally substituted heterocyclic ring, or -CO-  
N(R<sub>14</sub>)R<sub>15</sub> wherein R<sub>14</sub> and R<sub>15</sub>, which may be the same or  
different, are hydrogen, optionally substituted straight-  
chained or branched C<sub>1-4</sub> alkyl, C<sub>3-7</sub> cycloalkyl, straight-  
chained or branched C<sub>1-4</sub> alkoxy, straight-chained or branched  
C<sub>1-4</sub>alkylsulfonyl or a heterocyclic ring, ~~carboxyl, straight-~~  
~~chained or branched C<sub>1-3</sub>alkyl having protected amino or an~~  
~~optionally substituted heterocyclic ring;~~  
or a ~~hydrate or~~ pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)

35. (Previously Presented) The compound according  
to claim 1, wherein the substitution of the optionally  
substituted straight-chained or branched C<sub>1-3</sub> alkyl as R<sub>7</sub> in  
formula (1) is halogen, hydroxyl or amino.